ERBB2 and invasive carcinoma: Unfortunately, immunotherapies targeting breast cancer are not immune from these general limitations as evidenced by the studies conducted by Hashimoto et al. Throughout the study, researchers examined six patients diagnosed with hormone receptor-positive and human epidermal growth factor receptor 2-negative invasive carcinoma.